Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Kenya has the seventh-largest number of people living with HIV in the world, at around 1.4 million, according to World Health ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

HIV commodities worth about Sh30 billion are lying at the Mombasa Road warehouses of the Mission for Essential Drugs & Supplies (MEDS), awaiting distribution, the NSDCC has said.The consignment ...

However, hope may be on the horizon as a radical new drug has potential to be released if it passes all trials. Lenacapavir, ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations., Hea ...

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...